Revance Therapeutics Inc. (RVNC) Has Surged To A New High On Study Results

Revance Therapeutics Inc. (RVNC) announced Tuesday morning that its two Phase 3 trials of RT002 injection met their primary and all secondary endpoints in patients with Glabellar lines.

Leave a Reply

Your email address will not be published.

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>